// App-Quantinova.ai

4108 : Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.

Researchers

Presenter

  • Andrew X. Zhu

Principal Investigators

  • Peter Malfertheiner

  • Joon Oh Park

  • Baek-Yeol Ryoo

  • Jae Yong Cho

  • Hyun Cheol Chung

  • Chung-Pin Li

  • Chia-Jui Yen

  • Kuan-Der Lee

  • Ling Yang

  • Denis Pezet

  • Florian Weissinger

  • Giovanni Brandi

  • Carlo Barone

  • Takuji Okusaka

  • Yoshiyuki Wada

  • Ian Chau

  • Masatoshi Kudo

  • Seiji Kawazoe

Medical Centers

  • Chang Gung Memorial Hospital, Taipei, Taiwan

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Saga Medical Center Koseikan, Saga, Japan.

  • National Cheng Kung University Hospital, Tainan City, Taiwan

  • Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

  • CHU, Clermond-Ferrand, France

  • Eli Lilly and Company, Bridgewater, NJ

  • National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

  • Policlinico S. Orsola Malphigi, Bologna, Italy

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, JapanRoyal Marsden, London & Surrey, United Kingdom

  • Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany

  • Otto-von-Guericke-Universitat Magdeburg, Magdeburg, Germany

  • Catholic University of the Sacred Heart, Rome, Italy

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • California Pacific Medical Center, San Francisco, CA

Locations

  • Taiwan

  • Japan

  • Italy

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Hepatic encephalopathy

  • Encephalopathy

  • Solid malignancies

Biomarkers

  • Alpha-fetoprotein

  • Carboxypeptidase B1

Drug/Treatment

  • Ramucirumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT01140347CP ACP AC

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved